One of the reasons people rarely recover from spinal cord injury is the scar tissue that develops, preventing nerve cells from reconnecting. But a new study from Zhigang He, PhD, of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital, demonstrated a way to minimize scar cell formation in adult mice after a spinal cord injury. The study, published in Nature, offers insights for new approaches to treating spinal cord injuries.
National Institutes of Health grant will enable Hedong Li to focus on role of micorRNAs in the reprogramming process
UNIVERSITY PARK, Pa. — Hedong Li, associate research professor of biology, has been awarded $1.8 million from the National Institutes of Health (NIH) to study how microRNAs — small segments of genetic material — could be used in treatments for spinal cord injury. The five-year grant builds upon previous work by Li and colleagues to convert glial cells, support cells that surround neurons, into functioning neurons.
Dorsal root ganglion stimulation evokes motor responses in patients with complete spinal cord injury
Bilateral L4 dorsal root ganglion (DRG) stimulation has been shown to evoke strong and reproducible motor responses in the upper leg in patients with chronic motor complete spinal cord injury (SCI).
In their paper published in Neuromodulation, authors Sadaf Soloukey and colleagues from Erasmus MC, Rotterdam, The Netherlands, refer to their study as the “first of its kind” to demonstrate the potential of the DRG as a new target for reproducible and potentially weight-bearing muscle recruitment in this particular cohort of patients.
Recently researchers discovered an axon guidance protein known as Plexin B2 in the central nervous system (CNS). During the spinal cord injury, this protein plays a significant role in the healing of the wound and neural repair.
The experiment was designed and conducted by the Icahn School of Medicine at Mount Sinai. This study could help the development of the treatments or therapies which target axon guidance pathways for treating the patients of Spinal cord injury more effectively.
Permanent neurological impairments can occur after spinal cord injury (SCI) due to the failure of the spinal cord motor and sensory axons to regenerate.
This is because the mammalian central nervous system (CNS), unlike in some amphibians and reptiles, has inhibitory molecules blocking growth post-development, as well as the lack of an effective regenerative response system. Within the peripheral nervous system (PNS), there is some limited axonal recovery that can occur naturally.
Chronic pain is a common and often debilitating problem that can significantly impact function and quality of life for patients with spinal cord injury.
To help find treatment solutions, UBC researchers are investigating the effectiveness of a drug called Targin at treating chronic pain in individuals with spinal cord injury. The research team is now recruiting study participants.
Potential First-in-Class Therapy for Chronic Spinal Cord Injury
NEW HAVEN, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) — ReNetX Bio announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track Designation for ReNetX Bio’s clinical therapy (AXER-204) for the potential treatment of Chronic Spinal Cord Injury (SCI). ReNetX Bio is currently conducting a Phase 1/2 clinical trial “RESET” in patients with SCI, with topline results expected in 2021.
Columbia engineers invent a robotic trunk-support-trainer to retrain patients with spinal cord injury to sit more stably and gain an expanded active sitting workspace
A new study led by a University of Calgary researcher at the Cumming School of Medicine (CSM) finds that fatigue and sleep may need more attention in order to prevent issues like stroke after spinal cord injury.
“People with spinal cord injury have alarming rates of stroke, and we wanted to understand why,” says study lead Dr. Aaron Phillips, Ph.D., assistant professor, in the Department of Physiology & Pharmacology, and member of the CSM’s Libin Cardiovascular Institute of Alberta and the Hotchkiss Brain Institute.
Feinstein Institutes research examines new closed-loop neurostimulation
MANHASSET, NY — Researchers at The Feinstein Institutes for Medical Research used new closed-loop neurostimulation methods and textile-based electrodes to facilitate individual finger movement and grasp force regulation in quadriplegia individuals. Their results were published in the Springer Nature journal, Bioelectronic Medicine.